We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
Read MoreHide Full Article
Key Takeaways
BIIB has started phase III dosing of felzartamab for primary membranous nephropathy in a global study.
The PROMINENT study will compare felzartamab to tacrolimus in 180 moderate-to-high-risk PMN patients.
Felzartamab showed antibody reduction and improved kidney markers in earlier phase II PMN studies.
Biogen (BIIB - Free Report) initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout is expected in 2029.
Felzartamab is an anti-CD38 antibody with a unique mechanism of action that is particularly relevant in PMN treatment. Currently, no approved therapies exist for PMN, and treatment typically relies on immunosuppressants or chemotherapy.
Felzartamab was added to Biogen’s pipeline with the acquisition of Human Immunology Biosciences (HI-Bio) last year. The candidate was originally developed by MorphoSys AG (acquired by Novartis), which out-licensed exclusive rights to develop and commercialize felzartamab to HI-Bio across all indications in all countries and territories, excluding China and certain other geographies.
BIIB’s Phase III PMN Study Design for Felzartamab
Biogen’s global phase III PROMINENT study will evaluate the efficacy and safety of felzartamab compared to an immunosuppressive drug, tacrolimus, in moderate-to-high-risk PMN patients in achieving complete remission of proteinuria (high levels of protein in the urine). The patient pool will include both newly diagnosed and relapsed cases.
Year to date, BIIB shares have plunged 17.9% compared with the industry’s decline of 3.6%.
Image Source: Zacks Investment Research
Biogen expects to enroll approximately 180 PMN patients in the PROMINENT study who will be randomized to receive either felzartamab or tacrolimus, with the primary endpoint being the percentage of patients who achieve complete remissions at week 104. The study will evaluate patients with and without a certain antibody (called anti-PLA2R) linked to PMN. Patients will be grouped based on how much of this antibody they have. As secondary endpoints, BIIB will also evaluate the effect of felzartamab on serum aPLA2R antibodies and patient-reported outcomes.
PMN is a serious kidney disease that can lead to kidney failure and affects about 36,000 people in the United States. It causes severe swelling, fatigue and infection risk. There are no approved treatments, and current options like immunosuppressants or chemotherapy fail in about one-third of patients, representing a serious unmet medical need.
In 2025, Biogen has also initiated dosing patients with felzartamab in two other phase III studies, TRANSCEND for late antibody-mediated rejection in adult kidney transplant recipients and PREVAIL for IgA nephropathy.
BIIB’s Felzartamab Shows Promise in Prior Studies
Biogen previously evaluated felzartamab in two phase II studies, M-PLACE and NewPLACE, focusing on patients with aPLA2R-positive PMN. In M-PLACE, most patients showed a significant drop in aPLA2R antibody levels within a week (median reduction of 45%), with most achieving more than 50% reduction by six months. The treatment also led to improvements in protein levels in urine and blood.
In both studies, side effects were primarily mild to moderate in severity and aligned with the candidate’s expected safety profile. The most common adverse event was infusion-related reactions following the first dose.
In the past 90 days, loss per share estimates for Immunocore’s 2025 have improved from $1.57 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.80 to $1.33 during the same period. IMCR stock has gained 6.4% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
In the past 90 days, Verona Pharma’s bottom-line estimates for 2025 have significantly improved from a loss of 7 cents per share to earnings of 22 cents. During the same timeframe, estimates for 2026 earnings per share have improved from $2.21 to $2.88. VRNA stock has surged 103.7% so far this year.
Verona Pharma’s earnings beat estimates in one of the trailing four quarters and missed the mark on the other three occasions, delivering an average negative surprise of 6.76%.
In the past 90 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $4.66 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $5.02 to $1.99. AGEN stock has soared 66.8% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
Key Takeaways
Biogen (BIIB - Free Report) initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout is expected in 2029.
Felzartamab is an anti-CD38 antibody with a unique mechanism of action that is particularly relevant in PMN treatment. Currently, no approved therapies exist for PMN, and treatment typically relies on immunosuppressants or chemotherapy.
Felzartamab was added to Biogen’s pipeline with the acquisition of Human Immunology Biosciences (HI-Bio) last year. The candidate was originally developed by MorphoSys AG (acquired by Novartis), which out-licensed exclusive rights to develop and commercialize felzartamab to HI-Bio across all indications in all countries and territories, excluding China and certain other geographies.
BIIB’s Phase III PMN Study Design for Felzartamab
Biogen’s global phase III PROMINENT study will evaluate the efficacy and safety of felzartamab compared to an immunosuppressive drug, tacrolimus, in moderate-to-high-risk PMN patients in achieving complete remission of proteinuria (high levels of protein in the urine). The patient pool will include both newly diagnosed and relapsed cases.
Year to date, BIIB shares have plunged 17.9% compared with the industry’s decline of 3.6%.
Image Source: Zacks Investment Research
Biogen expects to enroll approximately 180 PMN patients in the PROMINENT study who will be randomized to receive either felzartamab or tacrolimus, with the primary endpoint being the percentage of patients who achieve complete remissions at week 104. The study will evaluate patients with and without a certain antibody (called anti-PLA2R) linked to PMN. Patients will be grouped based on how much of this antibody they have. As secondary endpoints, BIIB will also evaluate the effect of felzartamab on serum aPLA2R antibodies and patient-reported outcomes.
PMN is a serious kidney disease that can lead to kidney failure and affects about 36,000 people in the United States. It causes severe swelling, fatigue and infection risk. There are no approved treatments, and current options like immunosuppressants or chemotherapy fail in about one-third of patients, representing a serious unmet medical need.
In 2025, Biogen has also initiated dosing patients with felzartamab in two other phase III studies, TRANSCEND for late antibody-mediated rejection in adult kidney transplant recipients and PREVAIL for IgA nephropathy.
BIIB’s Felzartamab Shows Promise in Prior Studies
Biogen previously evaluated felzartamab in two phase II studies, M-PLACE and NewPLACE, focusing on patients with aPLA2R-positive PMN. In M-PLACE, most patients showed a significant drop in aPLA2R antibody levels within a week (median reduction of 45%), with most achieving more than 50% reduction by six months. The treatment also led to improvements in protein levels in urine and blood.
In both studies, side effects were primarily mild to moderate in severity and aligned with the candidate’s expected safety profile. The most common adverse event was infusion-related reactions following the first dose.
Biogen Inc. Price and Consensus
Biogen Inc. price-consensus-chart | Biogen Inc. Quote
BIIB’s Zacks Rank & Stocks to Consider
Biogen currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) , Verona Pharma (VRNA - Free Report) and Agenus (AGEN - Free Report) . While IMCR and VRNA sport a Zacks Rank #1 (Strong Buy) each, AGEN carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 90 days, loss per share estimates for Immunocore’s 2025 have improved from $1.57 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.80 to $1.33 during the same period. IMCR stock has gained 6.4% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
In the past 90 days, Verona Pharma’s bottom-line estimates for 2025 have significantly improved from a loss of 7 cents per share to earnings of 22 cents. During the same timeframe, estimates for 2026 earnings per share have improved from $2.21 to $2.88. VRNA stock has surged 103.7% so far this year.
Verona Pharma’s earnings beat estimates in one of the trailing four quarters and missed the mark on the other three occasions, delivering an average negative surprise of 6.76%.
In the past 90 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $4.66 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $5.02 to $1.99. AGEN stock has soared 66.8% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.